Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population:Results from the Dutch Castration-resistant Prostate Cancer Registry

Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC patients, identify variables associated with overall survival (OS), and establish a prog-nostic model. Design, setting, and participants: Patients with mCRPC who were progressive on second-line LPD before July 1, 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December 3... Mehr ...

Verfasser: Notohardjo, Jessica C. L.
Kuppen, Malou C. P.
Westgeest, Hans M.
van Moorselaar, Reindert J. A.
Mehra, Niven
Coenen, Jules L. L. M.
van Oort, Inge M.
de Vos, Aad
Vervenne, Walter L.
van den Bergh, Alphons C. M.
Aben, Katja K. H.
Somford, Diederik M.
Bergman, Andries M.
Uyl-de Groot, Carin A.
Gerritsen, Winald R.
van den Eertwegh, Alfons J. M.
Dokumenttyp: Artikel
Erscheinungsdatum: 2021
Reihe/Periodikum: Notohardjo , J C L , Kuppen , M C P , Westgeest , H M , van Moorselaar , R J A , Mehra , N , Coenen , J L L M , van Oort , I M , de Vos , A , Vervenne , W L , van den Bergh , A C M , Aben , K K H , Somford , D M , Bergman , A M , Uyl-de Groot , C A , Gerritsen , W R & van den Eertwegh , A J M 2021 , ' Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population : Results from the Dutch Castration-resistant Prostate Cancer Registry ' , European Urology Focus , vol. 7 , no. 4 , pp. 788-796 . https://doi.org/10.1016/j.euf.2020.03.009
Schlagwörter: Life-prolonging drug / Real-world outcomes / Third line / Castration-resistant prostate cancer / ABIRATERONE ACETATE / ANTITUMOR-ACTIVITY / PROGNOSTIC MODEL / DOCETAXEL / ENZALUTAMIDE / SURVIVAL / CHEMOTHERAPY / MITOXANTRONE / CABAZITAXEL / PREDNISONE
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29027360
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/11370/271f8cdc-567a-4261-a2e6-6bb7d36cae23

Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC patients, identify variables associated with overall survival (OS), and establish a prog-nostic model. Design, setting, and participants: Patients with mCRPC who were progressive on second-line LPD before July 1, 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December 31, 2017. Outcome measurements and statistical analysis: Association of potential risk factors with OS was tested by Cox proportional hazard models after multiple imputation of missing baseline characteristics. A predictive score was computed from the regression coefficient and used to classify patients into risk groups. Results and limitations: Of 1011 mCRPC patients progressive on second-line LPD, 602 (60%) received third-line LPD. Patients receiving third-line LPD had a more favorable prognostic profile at baseline and longer median OS than patients with best supportive